SNM CMIIT Hosts Prostate Cancer Summit

NM's Center for Molecular Imaging Innovation and Translation (CMIIT) is hosting the Multimodality Molecular Imaging of Prostate Cancer summit on January 21. Part of the SNM Mid-Winter Meetings, this 1-d symposium in Palm Springs, CA, will bring together individuals from multiple clinical and scientific disciplines to provide an up-to-date survey of best practices for the diagnosis and treatment of patients with prostate cancer. The symposium will address the need for synergism among diagnostic radiology, nuclear medicine, and the new molecular imaging modalities. The overall goal is to educate the audience in state-of-the-art PET imaging for diagnosis, staging, and monitoring cancer therapies, as applied to the treatment of prostate cancer.

The speaker roster includes expert diagnostic radiologists, nuclear medicine physicians and scientists, and medical oncologists. Lectures will emphasize the role of imaging in enabling better treatment selection and evaluation, as well as ideal approaches to assessing response to treatment.

Small meetings such as this are ideal for fostering potential collaborations among scientists and clinicians working in related fields and for promoting the basic science research that constantly improves clinical applications. We hope that the tight focus on prostate cancer, combined with the wide scope of molecular imaging, will stimulate a lively conversation that will ultimately benefit patients and advance the state of the art.

Four sessions will cover applications of PET, MR, and bone scanning; new PET tracers; therapeutic approaches; and what's in store for the future in the development of probes and imaging modalities. Some of the talks to which I personally look forward include:

- Low Molecular Weight Imaging Agents for Prostate Cancer, by Martin G. Pomper MD, PhD (Johns Hopkins Medical School)
- Engineered Antibodies for ImmunoPET, by Anna M.
 Wu, PhD (University of California, Los Angeles)



Steven M. Larson, MD

- The Future of Clinical Imaging of Prostate Cancer, by Peter L. Choyke, MD (National Cancer Institute)
- L- and A-Type Amino Acid Transport in Prostate Carcinoma: anti-¹⁸F-FACBC and Other Radiotracers, by David M. Schuster, MD (Emory University School of Medicine)
- PET in Prostate Cancer, by Hossein Jadvar, MD, PhD (University of Southern California)
- MR Imaging of Prostate Cancer, by John Kurhanewicz, PhD (University of California, San Francisco)

All those whose research is applicable to the problems of prostate cancer will enjoy and benefit from this highly targeted symposium. Join us in Palm Springs on January 21.

Steven M. Larson, MD Symposium Chair and Moderator

(continued from page 15N)

- U.S. Food and Drug Administration. Guidance: PET drugs—current good manufacturing practice (CGMP). Available at: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070306.pdf. Accessed on November 24, 2010.
- Radiopharmaceutical for positron emission compounding-compounding (general chapter 823). In: USP 32-NF27: United States Pharmacopeia and National Formulary. Rockville, MD: United States Pharmacopeial Convention; 2009: 365–369.
- Draft guidance: PET drugs—current good manufacturing practice (CGMP). Washington, DC: U.S. Food and Drug Administration; 2005:3.
- U.S. Pharmacopeia. Chromatography (general chapter 621). Available at: www. uspnf.com/uspnf/pub/index?usp=33&nf=28&s=1&officialOn=October%201,% 202010. Accessed on November 24, 2010, access available only to subscribers.
- 8. *U.S. Pharmacopeia.* Hot topics: USP general chapter <823> radiopharmaceuticals for positron emission tomography-compounding. Available at: www.usp.org/hottopics/uspGeneralChapter823.html. Accessed on November 24, 2010.

Joseph C. Hung, PhD Mayo Clinic Rochester, MN